PT2774991T - Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos - Google Patents

Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos

Info

Publication number
PT2774991T
PT2774991T PT130014913T PT13001491T PT2774991T PT 2774991 T PT2774991 T PT 2774991T PT 130014913 T PT130014913 T PT 130014913T PT 13001491 T PT13001491 T PT 13001491T PT 2774991 T PT2774991 T PT 2774991T
Authority
PT
Portugal
Prior art keywords
diagnosis
treatment
delivery system
drug delivery
neurological disorders
Prior art date
Application number
PT130014913T
Other languages
English (en)
Inventor
Demina Victoria
Manninga Heiko
Götzke Armin
Glassmann Alexander
Original Assignee
Life Science Inkubator Betr Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Science Inkubator Betr Gmbh & Co Kg filed Critical Life Science Inkubator Betr Gmbh & Co Kg
Publication of PT2774991T publication Critical patent/PT2774991T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041Use of virus, viral particle or viral elements as a vector
    • C12N2710/22042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041Use of virus, viral particle or viral elements as a vector
    • C12N2710/22043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22071Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24071Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT130014913T 2012-03-06 2013-03-22 Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos PT2774991T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12001507.8A EP2636746A1 (en) 2012-03-06 2012-03-06 A novel drug delivery system based on JCV-VLP
PCT/EP2013/000656 WO2013131644A1 (en) 2012-03-06 2013-03-06 A novel drug delivery system based on jcv-vlp

Publications (1)

Publication Number Publication Date
PT2774991T true PT2774991T (pt) 2018-03-07

Family

ID=48047958

Family Applications (2)

Application Number Title Priority Date Filing Date
PT137141958T PT2823048T (pt) 2012-03-06 2013-03-06 Um sistema inovador de entrega de fármaco com base em vlp de jcv
PT130014913T PT2774991T (pt) 2012-03-06 2013-03-22 Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT137141958T PT2823048T (pt) 2012-03-06 2013-03-06 Um sistema inovador de entrega de fármaco com base em vlp de jcv

Country Status (25)

Country Link
US (3) US20150045417A1 (pt)
EP (3) EP2636746A1 (pt)
JP (1) JP6175080B2 (pt)
KR (1) KR102058488B1 (pt)
CN (1) CN104395475B (pt)
AU (1) AU2013230232B2 (pt)
BR (1) BR112014021497A2 (pt)
CA (1) CA2865564C (pt)
CY (1) CY1120150T1 (pt)
DK (2) DK2823048T3 (pt)
EA (1) EA035308B1 (pt)
ES (2) ES2658941T3 (pt)
HK (1) HK1208046A1 (pt)
HR (1) HRP20180221T1 (pt)
HU (2) HUE038284T2 (pt)
LT (1) LT2823048T (pt)
MX (1) MX354004B (pt)
NO (1) NO2823048T3 (pt)
NZ (1) NZ629255A (pt)
PL (1) PL2823048T3 (pt)
PT (2) PT2823048T (pt)
SG (3) SG11201405255SA (pt)
SI (1) SI2823048T1 (pt)
TR (1) TR201802849T4 (pt)
WO (1) WO2013131644A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031821A1 (en) * 2014-12-08 2016-06-15 Life Science Inkubator polyomavirus VLPs with a fusion protein
EP3031820A1 (en) * 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
WO2017072303A1 (en) * 2015-10-28 2017-05-04 Life Science Inkubator Gmbh Use of vlp for the detection of nucleic acids
CN106048093A (zh) * 2016-08-02 2016-10-26 北京思尔成生物技术有限公司 Jc病毒的检测方法、试剂盒及其应用
DK3688147T3 (da) * 2018-12-18 2022-12-19 Neuway Pharma Gmbh Hidtil ukendt lægemiddelindgivelsessystem og fremgangsmåder til tilvejebringelse heraf
EP3670652A1 (en) * 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp for the treatment of a lysosomal storage disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE69821227D1 (de) 1997-04-26 2004-02-26 Rpms Technology Ltd Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE19916224C1 (de) 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
EP2036980A1 (de) 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2093780B1 (en) 2008-02-22 2014-11-05 ABB Technology AG A spring drive unit, an operating device for an electrical switching apparatus, and method for charging and/or discharging a spring in an operating device for an electrical switching apparatus
EP2394163B1 (en) * 2009-02-05 2020-08-19 Biogen MA Inc. Methods for the detection of jc polyoma virus

Also Published As

Publication number Publication date
PT2823048T (pt) 2018-02-09
CN104395475A (zh) 2015-03-04
ES2661389T3 (es) 2018-03-28
US20190201549A1 (en) 2019-07-04
SG10202102293QA (en) 2021-04-29
SI2823048T1 (en) 2018-04-30
HRP20180221T1 (hr) 2018-04-20
EA035308B1 (ru) 2020-05-27
AU2013230232B2 (en) 2019-01-03
LT2823048T (lt) 2018-02-26
US11291735B2 (en) 2022-04-05
CA2865564A1 (en) 2013-09-12
NO2823048T3 (pt) 2018-04-07
EP3299468A1 (en) 2018-03-28
NZ629255A (en) 2016-09-30
WO2013131644A8 (en) 2013-12-12
PL2823048T3 (pl) 2018-05-30
MX354004B (es) 2018-02-08
CA2865564C (en) 2021-06-08
TR201802849T4 (tr) 2018-03-21
US20150045417A1 (en) 2015-02-12
EP2636746A1 (en) 2013-09-11
SG10201607358WA (en) 2016-10-28
DK2774991T3 (en) 2018-03-12
AU2013230232A1 (en) 2014-10-02
MX2014010651A (es) 2015-05-15
CN104395475B (zh) 2018-11-16
EP2823048A1 (en) 2015-01-14
DK2823048T3 (en) 2018-02-12
KR20150003186A (ko) 2015-01-08
HUE038284T2 (hu) 2018-10-29
EP2823048B1 (en) 2017-11-08
EA201491636A1 (ru) 2015-05-29
ES2658941T3 (es) 2018-03-13
US20180296700A1 (en) 2018-10-18
JP2015513550A (ja) 2015-05-14
HK1208046A1 (en) 2016-02-19
CY1120150T1 (el) 2018-12-12
HUE038580T2 (hu) 2018-10-29
JP6175080B2 (ja) 2017-08-02
WO2013131644A1 (en) 2013-09-12
BR112014021497A2 (pt) 2019-07-16
AU2013230232A9 (en) 2018-12-13
KR102058488B1 (ko) 2019-12-23
SG11201405255SA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
HK1213503A1 (zh) 藥物遞送醫療裝置
HK1205928A1 (en) Ocular drug delivery system
HK1209456A1 (en) Oligonucleotide for the treatment of muscular dystrophy patients
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
IL237649B (en) Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint
SI2838539T1 (sl) Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj
HK1184370A1 (zh) 用於治療疼痛的藥物組合
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
EP2709670A4 (en) TARGETED ADMINISTRATION OF PROTEINS ACROSS THE HEMATO-ENCEPHALIC BARRIER
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EP2776042A4 (en) DRUG POLYTHERAPY FOR THE TREATMENT OF SOLID TUMORS
EP2819741A4 (en) SOLVENT MEDICINAL IMPLANTS FOR THE INTRACOCHLEAR RELEASE OF THERAPEUTICS FOR THE TREATMENT OF EARLIER DISEASES
HUE038580T2 (hu) Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
LT2774991T (lt) Vaisto įvedimo sistema, skirta naudoti neurologinių sutrikimų gydymui arba diagnostikai
PL2861568T3 (pl) Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca
EP2869796A4 (en) PATIENT TREATMENT SYSTEM
ZA201306759B (en) Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
HK1202239A1 (en) Combination drug therapy for the treatment of solid tumors